Key result
Elevated high-sensitivity troponin was not an independent predictor of mortality in COVID-19 patients, whereas lower PaO2/FiO2 independently predicted death (HR 0.901; 95% CI 0.829-0.978; P=0.0133).
Why the study?
Controversial data existed regarding the prognostic role of cardiac troponins in patients hospitalized for COVID-19.
Does elevated high-sensitivity troponin at admission predict all-cause mortality in patients hospitalized for COVID-19 when accounting for respiratory function?
Population
722 unselected patients hospitalized for COVID-19
Comparison
High-sensitivity troponin levels and PaO2/FiO2 at admission
Design
Individual patient data meta-analysis of observational studies
Follow-up
Median 14 days
Authors
Loading...
Troponin elevation does not independently predict COVID-19 mortality after respiratory adjustment; challenges its standalone prognostic value and prioritizes oxygenation metrics.
Meta-Analysis (n=722)
Yes
Does elevated high-sensitivity troponin at admission predict all-cause mortality in patients hospitalized for COVID-19 when accounting for respiratory function?
Hazard Ratio: 0.901 (95% CI 0.829–0.978)
p-value: p=0.0133
In patients hospitalized for COVID-19, elevated high-sensitivity troponin is not an independent predictor of mortality after adjusting for respiratory failure.
Ghio et al. (2021) conducted a meta-analysis in COVID-19 (n=722). High-sensitivity troponin and PaO2/FiO2 at admission was evaluated on All-cause mortality (HR 0.901, 95% CI 0.829-0.978, p=0.0133). Elevated high-sensitivity troponin was not an independent predictor of mortality in COVID-19 patients, whereas lower PaO2/FiO2 independently predicted death (HR 0.901; 95% CI 0.829-0.978; P=0.0133).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: